FDA OKs expanded age for Novartis' Menveo vaccine

08/2/2013 | Pharmaceutical Business Review Online

The FDA approved the use of Novartis' meningococcal conjugate vaccine Menveo to include toddlers and infants 2 months and older. The vaccine provides protection against meningococcal disease related to four strains of Neisseria meningitidis. The expanded approval was based on data from three trials involving more than 8,700 infants.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Associate Manager, Regulatory Affairs
Stryker
Mahwah, NJ
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC